David B. Agus, MD

Professor of Medicine and Biomedical Engineering

Director, Lawrence J. Ellison Institute for Transformative Medicine of USC

Director, USC Center for Applied Molecular Medicine

Websites

Is this your profile? Click to edit

Overview

David B. Agus is a professor of medicine and engineering at the University of Southern California’s Keck School of Medicine and Viterbi School of Engineering. He is the founding director and CEO of the Lawrence J. Ellison Institute for Transformative Medicine. A medical oncologist, Dr. Agus leads a multidisciplinary team of researchers dedicated to the development and use of technologies to guide doctors in making health-care decisions tailored to individual needs. An international leader in new technologies and approaches for personalized healthcare, Dr. Agus serves in leadership roles at the World Economic Forum and the Global Health Security Consortium. He is also a CBS News contributor. Dr. Agus’ three books “The End of Illness”, “A Short Guide to a Long Life” and “The Lucky Years: How to Thrive in the Brave New World of Health” are all New York Times and international bestsellers. Dr. Agus graduated cum laude with honors in molecular biology from Princeton University, and received his medical degree from the University of Pennsylvania School of Medicine. He completed his medical internship and residency training at Johns Hopkins Hospital and fellowship at Memorial Sloan-Kettering Cancer Center.

Awards

American Cancer Society: Physician Research Award, 1996
– 2001
Sloan-Kettering Institute: Clinical Scholar Award, 1996
American Cancer Society: Clinical Oncology Fellowship Award, 1994
HealthNetwork Foundation: Excellence Award, 2008
Geoffrey Beene Foundation: Rock Stars of Science™, 2009
Biotech Humanitarian Award: Selected Judge, 2009
USC Association of Trojan Leagues: Outstanding Service Award, 2013
American College of Physicians: Fellow, 2016
Ellis Island Medal of Honor: Medalist, 2017

Research Funding

(PQB6)An Integrative Computational and Bioengineered Tissue Model of Metastasis
NIH · R01CA180149 · Sep 5, 2013 – Jul 31, 2018 · Role: Principal Investigator
UCLA SPORE in Prostate Cancer
NIH · P50CA092131 · Jul 1, 2001 – Aug 31, 2024 · Role: Co-Principal Investigator

Media

Sixty-five simple rules to maintain good health (1/8/2014)
Agus relishes his role as a health care rebel (10/11/2012)
Agus' book focuses on new view of health (1/17/2012)
USC Welcomes Oncologist David Agus (06/30/2009)

Publications

Cancer-associated fibroblasts derived from EGFR-TKI-resistant tumors reverse EGFR pathway inhibition by EGFR-TKIs. Mol Cancer Res. 2010 Jun; 8(6):809-20.. View in PubMed
HER kinase axis receptor dimer partner switching occurs in response to EGFR tyrosine kinase inhibition despite failure to block cellular proliferation. Cancer Res. 2010 Mar 01; 70(5):1989-99.. View in PubMed
Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes. Mol Cancer Ther. 2009 Oct; 8(10):2882-93.. View in PubMed
Predictors of affect following treatment decision-making for prostate cancer: conversations, cognitive processing, and coping. Psychooncology. 2009 May; 18(5):508-14.. View in PubMed
Multiparameter computational modeling of tumor invasion. Cancer Res. 2009 May 15; 69(10):4493-501.. View in PubMed
Precursor-ion mass re-estimation improves peptide identification on hybrid instruments. J Proteome Res. 2008 Sep; 7(9):4031-9.. View in PubMed
ProteoWizard: open source software for rapid proteomics tools development. Bioinformatics. 2008 Nov 01; 24(21):2534-6.. View in PubMed
Personalized genetics: a responsible approach. Am J Hum Genet. 2008 Jul; 83(1):130.. View in PubMed
The current state of preclinical prostate cancer animal models. Prostate. 2008 May 01; 68(6):629-39.. View in PubMed
A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer. BMC Cancer. 2007 Jul 27; 7:142.. View in PubMed